Log in

Relevant bibliographies by topics / Relapsers / Journal articles

To see the other types of publications on this topic, follow the link: Relapsers.

Journal articles on the topic 'Relapsers'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Relapsers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Freedman, MS, S. Broadley, A. Chinea, et al. "A.03 Durable clinical and MRI efficacy of alemtuzumab over 6 years in CARE-MS II patients with RRMS who relapsed between Courses 1 and 2." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 45, s2 (2018): S10. http://dx.doi.org/10.1017/cjn.2018.84.

Full text

Abstract:

Background: In RRMS patients with inadequate response to prior therapy, 2 alemtuzumab courses (12 mg/day; baseline: 5 days; 12 months later: 3 days) significantly improved outcomes over 2 years (y) versus SC IFNB-1a (CARE-MS II [NCT00548405]), with durable efficacy over a 4-y extension (NCT00930553). We present 6-y efficacy (2-y core study plus 4-y extension) in patients with relapse (relapsers) between Courses (C) 1 and 2. Methods: Annualized relapse rate (ARR); 6-month confirmed disability worsening (CDW); MRI disease activity (Gd-enhancing lesions; new/enlarging T2 hyperintense lesions); br

APA, Harvard, Vancouver, ISO, and other styles

2

Minj, Simpal Shalini, Surbhi Rathi, Santosh Kondekar, and Jane J. E. David. "Study of risk factors for relapse in frequently versus infrequently relapsing nephrotic syndrome in 1-18 year age group: a combined prospective retrospective cohort analytical observational study." International Journal of Contemporary Pediatrics 6, no. 2 (2019): 803. http://dx.doi.org/10.18203/2349-3291.ijcp20190733.

Full text

Abstract:

Background: Early prediction and prevention of risk factors is the key to successful management of childhood nephrotic syndrome. This study was carried out to find the risk factors of relapse which will help in early prediction and reduce the risk of relapse in childhood nephrotic syndrome.Methods: It was a combined prospective-retrospective cohort analytical observational study of duration 18 months with sample size of 80 patients of age group 1-18 years who fulfilled the inclusion and exclusion criteria. The variables taken into account for the present study were demographic and disease rela

APA, Harvard, Vancouver, ISO, and other styles

3

Sangeetha, A., S. Sudhakar, I. Ilavarasan, and P. P. Kannan. "A follow – Up study on coping strategies and its association with relapse among alcohol dependent patients." Panacea Journal of Medical Sciences 14, no. 2 (2024): 446–52. http://dx.doi.org/10.18231/j.pjms.2024.080.

Full text

Abstract:

Alcohol consumption is a major problem in India. Alcohol dependence develops due to various factors, like individuals’ characteristics and social factors. The study was done to analyze coping strategies in relation to alcohol dependence and relapse.A follow-up study was conducted among 103 patients who attended the Psychiatry department for de – addiction treatment in a tertiary care centre in Chengalpattu, Tamil Nadu. A validated semi-structured questionnaire was used to collect details of Socio-demographic characteristics. The Severity of Alcohol Dependence Questionnaire and the Brief-COPE q

APA, Harvard, Vancouver, ISO, and other styles

4

Shilliday, I. R., K. Simpson, R. Jackson, A. L. McLay, and M. Boulton-Jones. "Minimal Change Nephropathy in the West of Scotland: A Review of Sixty-Four Patients." Scottish Medical Journal 38, no. 3 (1993): 70–72. http://dx.doi.org/10.1177/003693309303800303.

Full text

Abstract:

Sixty-four patients with a histological diagnosis of minimal change nephropathy have been followed for a median of 110 months. Patients transferred from paediatric units (11%) had a worse prognosis in that all became frequent relapsers. Patients who relapsed within three months or who went on to become frequent relapsers had a higher 24 hour urine protein excretion at presentation than patients who did not relapse. After fifteen months of remission relapse was rare; 97% of those who relapsed did so within 36 months. Patients who have been off steroids and proteinuria free for 36 months might t

APA, Harvard, Vancouver, ISO, and other styles

5

Nassif, Elise F., Chia-Chin Wu, Kadir Akdemir, et al. "Abstract PR002: Antigen presentation and processing pathway is associated with early relapse after neoadjuvant immune checkpoint blockade (ICB) in dedifferentiated liposarcomas (DDLPS)." Clinical Cancer Research 28, no. 18_Supplement (2022): PR002. http://dx.doi.org/10.1158/1557-3265.sarcomas22-pr002.

Full text

Abstract:

Abstract Background: We evaluated the activity of neoadjuvant ICB in localized resectable DDLPS (n=17) and undifferentiated pleomorphic sarcomas (UPS; n=10). DDLPS and UPS patients were randomized to neoadjuvant nivolumab or ipilimumab+nivolumab, with UPS patients receiving concurrent radiotherapy. We assessed genomic markers of early relapse (progression before surgery or relapse within 52 weeks following surgery) using longitudinally acquired tumor samples. Methods: RNA sequencing (RNAseq) and whole genome sequencing (WGS) were performed on longitudinally acquired samples (baseline biopsies

APA, Harvard, Vancouver, ISO, and other styles

6

Van Wijmeersch, Bart, Barry A. Singer, Aaron Boster, et al. "Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies." Multiple Sclerosis Journal 26, no. 13 (2019): 1719–28. http://dx.doi.org/10.1177/1352458519881759.

Full text

Abstract:

Background: Alemtuzumab is administered as two annual courses for relapsing–remitting multiple sclerosis (MS). Patients may relapse before completing the two-course regimen. Objective: The objective was to evaluate 6-year outcomes in patients who relapsed between alemtuzumab Courses 1 and 2 (early relapsers). Methods: Post hoc analysis of patients from the Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis (CARE-MS) studies who enrolled in the extension. Results: Early relapsers (CARE-MS I: 15%; CARE-MS II: 24%) had more relapses in 1–2 years pre-alemtuzumab and higher mean ba

APA, Harvard, Vancouver, ISO, and other styles

7

Massimino, Maura, Francesca Romana Buttarelli, Hendrik Witt, et al. "EPEN-03. LONG-TERM FOLLOW-UP OF AIEOP 2ND SERIES OF CHILDREN AND ADOLESCENT WITH PRIMARY INTRACRANIAL (ST:SUPRATENTORIAL; PF: POSTERIOR FOSSA) EPENDYMOMA AND METHYLATION GROUPS RE-ANALYSES." Neuro-Oncology 22, Supplement_3 (2020): iii308. http://dx.doi.org/10.1093/neuonc/noaa222.144.

Full text

Abstract:

Abstract BACKGROUND This 2002–2014 Italian prospective study stratified 160 patients by surgical resection (complete=NED/incomplete=ED) and centrally-reviewed grade. Grade2/NED patients received focal radiotherapy (RT) up to 59.4Gy, Grade3/NED received 4 courses of VEC(vincristine,etoposide,cyclophosphamide) after RT.ED patients received 1–4 VEC courses, second-look surgery, 59.4 Gy+8Gy boost on measurable residue. METHODS We re-analyzed data at 115 months follow-up including methylation profile on available samples. RESULTS Global PFS/OS at 5/10 years were 66/59% and 80/74%, respectively. Of

APA, Harvard, Vancouver, ISO, and other styles

8

Berti, A., S. Hillion, A. Hummel, et al. "THU0040 PROTEINASE 3-REACTIVE B CELL RECONSTITUTION AFTER TREATMENT WITH RITUXIMAB FOR ANCA-ASSOCIATED VASCULITIS." Annals of the Rheumatic Diseases 79, Suppl 1 (2020): 233.1–233. http://dx.doi.org/10.1136/annrheumdis-2020-eular.5169.

Full text

Abstract:

Background:Proteinase 3 (PR3)-reactive B cells are present in PR3-ANCA-associated vasculitis (AAV) at levels higher than healthy controls.Objectives:To evaluate the dynamics of the PR3-reactive B cell repopulation in patients with PR3-AAV after treatment with rituximab, and to analyze possible associations between these immunological changes and long-lasting remissions.Methods:We analyzed all available frozen peripheral blood mononuclear cells (n=148) from 23 randomly-selected PR3-AAV patients who participated in the RAVE trial and achieved complete remission (BVAS=0, prednisone=0) after treat

APA, Harvard, Vancouver, ISO, and other styles

9

Soman, S., and A. Vr. "The prevalence of psychiatric comorbidities and relapses in males treated for alcohol dependence syndrome – Prospective study from tertiary de-addiction care unit in Kerala, India." European Psychiatry 41, S1 (2017): s879. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1774.

Full text

Abstract:

Kerala has high percapita consumption of alcohol among the other Indian states.ObjectivesPrevalence of psychiatric comorbidities in alcohol dependence syndrome and association of severity of alcohol dependence, personality dimensions, motivation and short delay relapses.MethodsA prospective study in 91 male alcoholic patients for 2 months.ResultsTwo groups not relapsed (NR = 48) and Relapsed (R = 43) were comparable in age, SADQ severity score, average units of alcohol consumption and years of alcohol use. Average consumption was 17 units/day (500 mL spirits), age of onset before 25 years 87%,

APA, Harvard, Vancouver, ISO, and other styles

10

Murphy, E., J. Douglas, Q. Qi, and L. Wood. "Relapse patterns and outcomes in a population-based study of Nova Scotia patients with germ cell tumors (GCT)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 15564. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.15564.

Full text

Abstract:

15564 Objectives: To examine the frequency and pattern of relapse in a population-based cohort of Nova Scotia patients with germ cell tumors (GCT). Presentation and outcome of these patients will be described with an emphasis on late relapsers. Methods: A retrospective chart review of all patients diagnosed with GCT in Nova Scotia between 1984 and 2004 was completed. Data regarding initial diagnosis and treatment as well as data at time of relapse was collected. Relapse was defined as any recurrence of tumor after initial definitive therapy. Late relapse (LR) was defined as a relapse >2 yea

APA, Harvard, Vancouver, ISO, and other styles

11

Lionaki, Sophia, Evangelos Mantios, Ioanna Tsoumbou, et al. "Clinical Characteristics and Outcomes of Adults with Nephrotic Syndrome Due to Minimal Change Disease." Journal of Clinical Medicine 10, no. 16 (2021): 3632. http://dx.doi.org/10.3390/jcm10163632.

Full text

Abstract:

Purpose: Minimal change disease (MCD) is considered a relatively benign glomerulopathy, as it rarely progresses to end-stage kidney disease. The aim of this study was to describe the characteristics and outcomes of adults with MCD and identify potential risk factors for relapse. Patients & Methods: We retrospectively studied a cohort of adults with biopsy-proven MCD in terms of clinical features and treatment outcomes. Baseline characteristics and outcomes were recorded and predictors of relapse were analyzed using logistic regression multivariate analysis. Results: 59 patients with adult-

APA, Harvard, Vancouver, ISO, and other styles

12

Souza, Suiane Lima de, Luãnna Liebscher Vidal, Juliene Ramos, et al. "Hepatitis C Virus-Infected Responders and Relapsers to Treatment Show Similar Genetic Profiles ofIL28BandIL10Single Nucleotide Polymorphisms." BioMed Research International 2018 (2018): 1–7. http://dx.doi.org/10.1155/2018/2931486.

Full text

Abstract:

Genotype 1 of hepatitis C virus (HCV) is the most prevalent worldwide. Pegylated-interferon and ribavirin therapy is still used in the developing world but has less efficiency in this genotype. Single nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 (IL28B) and rs1800896, rs1800871, and rs1800872 (IL10) are related to treatment outcome, but previous studies clustered nonresponse and relapse patients. The aim of this study is to analyze the frequency of those SNPs in HCV genotype 1 for response, nonresponse, or relapse. Patients were classified according to treatment outcome. Genomic DN

APA, Harvard, Vancouver, ISO, and other styles

13

Albaqami, Walaa F., Ali A. Alshamrani, Ali A. Almubarak, et al. "Genetic and Epigenetic Biomarkers Associated with Early Relapse in Pediatric Acute Lymphoblastic Leukemia: A Focused Bioinformatics Study on DNA-Repair Genes." Biomedicines 12, no. 8 (2024): 1766. http://dx.doi.org/10.3390/biomedicines12081766.

Full text

Abstract:

Genomic instability is one of the main drivers of tumorigenesis and the development of hematological malignancies. Cancer cells can remedy chemotherapeutic-induced DNA damage by upregulating DNA-repair genes and ultimately inducing therapy resistance. Nevertheless, the association between the DNA-repair genes, drug resistance, and disease relapse has not been well characterized in acute lymphoblastic leukemia (ALL). This study aimed to explore the role of the DNA-repair machinery and the molecular mechanisms by which it is regulated in early- and late-relapsing pediatric ALL patients. We perfo

APA, Harvard, Vancouver, ISO, and other styles

14

Ali, Shatha, Hayder Ali, and Alaa Neamah. "Risk Factors for Relapses in Children with Steroid Sensitive Nephrotic Syndrome." Iraqi Journal of Medical Sciences 20, no. 2 (2022): 226–32. http://dx.doi.org/10.22578/ijms.20.2.9.

Full text

Abstract:

Background: Nephrotic syndrome (NS) is the most common glomerular disease seen in the pediatric age group. Objective: To study demographic, socioeconomic, disease related characteristics and the physical examination including height, weight and blood pressure correlation with frequency of relapses in children with steroid sensitive NS (SSNS). Methods: This is a cross sectional study that was conducted at Nephrology Consultation Clinic, in Al-Imamein Al-kadhimein (peace on them) Medical City, Baghdad, Iraq starting from 1st of January, 2020 to 31 July, 2021. Results: Total number of patients wa

APA, Harvard, Vancouver, ISO, and other styles

15

Mateos, Maria-Victoria, Hartmut Goldschmidt, Jesus F. San-Miguel, et al. "Carfilzomib in Relapsed or Refractory Multiple Myeloma Patients with Early or Late Relapse Following Prior Therapy: An Analysis of Overall Survival in Subgroups from the Randomized Phase 3 Aspire and Endeavor Trials." Blood 132, Supplement 1 (2018): 1964. http://dx.doi.org/10.1182/blood-2018-99-112189.

Full text

Abstract:

Abstract Introduction: Carfilzomib is an irreversible proteasome inhibitor with proven efficacy as a single agent and in doublet and triplet combinations (Siegel et al, Blood. 2012;120:2817-25; Dimopoulos et al, Lancet Oncol. 2017;18:1327-37; Siegel et al, J Clin Oncol. 2018;36:728-34). The phase 3 ASPIRE and ENDEAVOR trials demonstrated that treatment with carfilzomib-based regimens led to superior efficacy outcomes (progression-free survival [PFS], overall survival [OS], and overall response rate [ORR]) compared with standard regimens in patients (pts) with relapsed or refractory multiple my

APA, Harvard, Vancouver, ISO, and other styles

16

Almousawi, F., M. Butler, P. Bedard, A. Spreafico, L. Siu, and M. Cunningham. "A242 DELAYED STEROID TAPER MAY REDUCE RISK OF RELAPSE IN PATIENTS WITH IMMUNE CHECKPOINT INHIBITOR ASSOCIATED HEPATOTOXICIT." Journal of the Canadian Association of Gastroenterology 6, Supplement_1 (2023): 70–71. http://dx.doi.org/10.1093/jcag/gwac036.242.

Full text

Abstract:

Abstract Background Immune checkpoint inhibitors (ICI) have become the cornerstone of treatment of certain malignancies. However, they can result in systemic toxicities including hepatitis. Societal guidelines recommend initial management with high dose steroids, then a slow taper as hepatitis resolves. However, there is significant variation in steroid response with some patients experiencing a relapse of hepatitis as steroid doses are tapered (“steroid relapse”). Purpose Identify clinical features that predict relapse, and to explore variations in steroid management, in patients with ICI hep

APA, Harvard, Vancouver, ISO, and other styles

17

Higgins, Jacob, Fang Yin Lo, Michael J. Hipp, et al. "Duplex Sequencing with Patient-Specific Hybrid Capture Panels Reveals Ultra-Low Frequency Measurable Residual Disease in Pediatric Acute Myeloid Leukemia." Blood 136, Supplement 1 (2020): 31–32. http://dx.doi.org/10.1182/blood-2020-143062.

Full text

Abstract:

Sensitive and specific detection of measurable residual disease (MRD) after treatment in pediatric acute myeloid leukemia (AML) is prognostic of relapse and is important for clinical decision making. Mutation-based methods are increasingly being used, but are hampered by the limited number of common driver gene mutations to target as clone markers. Additional targets would greatly increase MRD detection power. However, even in cases with many AML-defining mutations, it is the limited accuracy of current molecular methods which establishes the lower bounds of sensitivity. Here we describe an ul

APA, Harvard, Vancouver, ISO, and other styles

18

Naismith, Graham D., Lyn A. Smith, Sarah J. E. Barry, et al. "A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn's disease." Journal of Crohn's and Colitis 8, no. 9 (2014): 1022–29. http://dx.doi.org/10.1016/j.crohns.2014.01.029.

Full text

Abstract:

Abstract Background Faecal calprotectin (FC) is a non-invasive marker of gastrointestinal inflammation. Aim To determine whether higher FC levels in individuals with quiescent Crohn's disease are associated with clinical relapse over the ensuing 12 months. Methods A single centre prospective study was undertaken in Crohn's disease patients in clinical remission. The receiver operating characteristic (ROC) curve for the primary endpoint of clinical relapse by 12 months, based on FC at baseline, was calculated. Kaplan–Meier curves of time to relapse were based on the resulting optimal FC cutoff

APA, Harvard, Vancouver, ISO, and other styles

19

Serat Jehan, Mohsina Noor Ibrahim, Khemchand N Moorani, Bilquis Abro, Bakhtawar Chandio, and Mehwish Riaz. "Factors associated with early relapses in children with steroid-sensitive nephrotic syndrome." Professional Medical Journal 31, no. 01 (2023): 61–66. http://dx.doi.org/10.29309/tpmj/2024.31.01.7777.

Full text

Abstract:

Objective: To determine different risk factors associated with relapse in children with steroid-sensitive nephrotic syndrome. Study Design: Cross-sectional study. Setting: Department of Pediatric Nephrology, The National Institute of Child Health, Karachi. Period: April 2021 to October 2022. Material & Methods: With a sample size of 170 Children aged 1-12 years of either gender were included in the study by non-probability consecutive sampling. Patients who had congenital nephrotic syndrome previously received immunosuppressive treatment or had any other systemic disease leading to nephrot

APA, Harvard, Vancouver, ISO, and other styles

20

Kroeger, Nils, Jae-Lyun Lee, Georg A. Bjarnason, et al. "Treatment response and survival outcome of patients with late relapse (LR) from renal cell carcinoma (RCC) in the era of targeted therapy." Journal of Clinical Oncology 31, no. 15_suppl (2013): 4578. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.4578.

Full text

Abstract:

4578 Background: A small subset of localized RCC patients will experience disease recurrence ≥5 years after nephrectomy. Clinical outcome of patients with LR has not been well characterized. Methods: Patients with mRCC treated with targeted therapy were retrospectively characterized according to time to relapse. Replase was defined as diagnosis of recurrent metastatic disease >3 months after initial diagnosis. Patients with synchronous metastatic disease at presentation were excluded. Patients were classified as Early Relapsers (ER) if they recurred within 5 years while Late Relapsers (LR)

APA, Harvard, Vancouver, ISO, and other styles

21

Ball, Geoff D. C., Jacqui R. Gingras, Andrea Fimrite, Karen Villetard, Susan Kayman, and Linda J. Mccargar. "Weight Relapsers, Maintainers, and Controls: Metabolic and Behavioural Differences." Canadian Journal of Applied Physiology 24, no. 6 (1999): 548–58. http://dx.doi.org/10.1139/h99-036.

Full text

Abstract:

The present investigation was undertaken to describe selected factors associated with the maintenance of body weight in three groups of women: relapsers (regained weight after losing weight), maintainers (maintained weight loss), and controls (weight stable). The following physiological variables were also assessed: resting energy expenditure (REE), serum glucose, insulin, leptin, triiodothyronine (T3), and body composition. As well, participants completed the interviewer-administered Weight Maintenance Questionnaire (WMQ). Overall, relapsers were older and heavier than maintainers and control

APA, Harvard, Vancouver, ISO, and other styles

22

Weisel, Katja, George F. Geils, Lionel Karlin, et al. "Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis of the Phase 3 Candor Study in Patients with Early or Late Relapse." Blood 136, Supplement 1 (2020): 37–38. http://dx.doi.org/10.1182/blood-2020-133908.

Full text

Abstract:

Introduction: Although outcomes for patients with multiple myeloma (MM) have improved with recent advances in treatment, relapse is still frequent. Early relapse is associated with poorer outcomes (Majithia et al., Leukemia 2016;30:2208-13) and is thought to reflect more aggressive disease, particularly within 12 months of autologous stem cell transplantation (ASCT). In the randomized phase 3 CANDOR study, progression-free survival (PFS) was significantly improved in patients with relapsed or refractory MM (RRMM) receiving carfilzomib, dexamethasone, and daratumumab (KdD) compared with carfilz

APA, Harvard, Vancouver, ISO, and other styles

23

Jacobson, Ira. "Management of interferon relapsers." American Journal of Medicine 107, no. 6 (1999): 62–66. http://dx.doi.org/10.1016/s0002-9343(99)00385-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Ott, Andrea, Erol Tutdibi, Sybelle Goedicke-Fritz, Jakob Schöpe, Michael Zemlin, and Nasenien Nourkami-Tutdibi. "Serum cytokines MCP-1 and GCS-F as potential biomarkers in pediatric inflammatory bowel disease." PLOS ONE 18, no. 11 (2023): e0288147. http://dx.doi.org/10.1371/journal.pone.0288147.

Full text

Abstract:

Background Inflammatory bowel diseases (IBDs) with the subtypes ulcerative colitis (UC) and Crohn disease (CD), are chronic autoimmune inflammatory disorders of the gastrointestinal tract. Cytokines are associated with the development and progression in pediatric IBD. We measured cytokine levels in pediatric IBD patients to assess their potential function as biomarkers in disease assessment. Method In this prospective cohort study, we enrolled 33 children with IBD. All patients were in stable remission for 3 months on enrollment. Patients who developed a relapse within six months after enrollm

APA, Harvard, Vancouver, ISO, and other styles

25

Junghanns, Klaus, Jutta Backhaus, Ulrike Tietz, et al. "The consumption of cigarettes, coffee and sweets in detoxified alcoholics and its association with relapse and a family history of alcoholism." European Psychiatry 20, no. 5-6 (2005): 451–55. http://dx.doi.org/10.1016/j.eurpsy.2004.09.011.

Full text

Abstract:

AbstractThirty male alcohol dependent inpatients without concurrent depressive disorder, 13 of them with a positive family history of alcohol dependence in a first degree relative (PFH), were questioned about their desire and consumption habits with respect to cigarettes, coffee, and sweets while on a three-week inpatient treatment after detoxification from alcohol. Six weeks after discharge from hospital, the patients were reassessed for relapse. Eleven patients (36.6%) had relapsed at follow-up. Relapsers were younger than abstainers. The days until relapse correlated negatively with intensi

APA, Harvard, Vancouver, ISO, and other styles

26

Yoshida, Eric M., Morris Sherman, Vincent G. Bain, et al. "Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy." Canadian Journal of Gastroenterology 23, no. 3 (2009): 180–84. http://dx.doi.org/10.1155/2009/470532.

Full text

Abstract:

BACKGROUND: Pegylated interferon (pegIFN) and ribavirin combination therapy remains the first-line treatment for chronic hepatitis C virus (HCV) infection. In contrast to the wealth of studies in treatment-naive patients, the effectiveness of retreatment in patients who have previously failed pegIFN-based therapy is largely unreported.AIM: To assess the effectiveness of the retreatment of patients who have previously failed an initial course of pegIFN-based therapy with pegIFNα-2a and ribavirin.METHODS: A post-hoc analysis of a multicentre open-label study was performed. Patients received pegI

APA, Harvard, Vancouver, ISO, and other styles

27

Chaparro, M., M. García Donday, A. Núñez Ortiz, et al. "DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry." Journal of Crohn's and Colitis 18, Supplement_1 (2024): i222—i225. http://dx.doi.org/10.1093/ecco-jcc/jjad212.0120.

Full text

Abstract:

Abstract Background IBD remission is key for pregnancy outcomes. Previous studies have suggested a disease recurrence risk of approximately 30% in patients in remission at conception, but this could be influenced by disease control in the periconceptional period and the discontinuation of treatments for IBD during pregnancy. Aim To provide updated data on the incidence of disease relapse during pregnancy in IBD patients and to identify predictive factors of relapse. Methods Pregnant patients with IBD from DUMBO registry were included. DUMBO is a prospective, observational, and multicentre regi

APA, Harvard, Vancouver, ISO, and other styles

28

Bodis, S., M. Henry-Amar, J. Bosq, et al. "Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols." Journal of Clinical Oncology 11, no. 2 (1993): 225–32. http://dx.doi.org/10.1200/jco.1993.11.2.225.

Full text

Abstract:

PURPOSE The great majority of relapses after the treatment for early-stage Hodgkin's disease are observed within 4 to 5 years after treatment completion. This study describes the characteristics and outcome of patients who had late relapses, which was defined as relapses that occurred 5 or more years after initial treatment start. PATIENTS AND METHODS A total of 1,082 adult patients with early clinical stage Hodgkin's disease were enrolled on three consecutive European Organization for Research and Treatment of Cancer (EORTC) protocols (H1, H2, and H5 trials) from 1964 to 1981. Of these, 1,044

APA, Harvard, Vancouver, ISO, and other styles

29

Lipschitz, Jessica M., Miryam Yusufov, Andrea Paiva, et al. "Transtheoretical Principles and Processes for Adopting Physical Activity: A Longitudinal 24-Month Comparison of Maintainers, Relapsers, and Nonchangers." Journal of Sport and Exercise Psychology 37, no. 6 (2015): 592–606. http://dx.doi.org/10.1123/jsep.2014-0329.

Full text

Abstract:

This study examined longitudinal differences in use of transtheoretical model (TTM) behavior change constructs in maintainers (who reached and maintained exercise guidelines), relapsers (who reached guidelines, then regressed), and nonchangers (who did not reach guidelines). Data from two population-based TTM-tailored randomized trial intervention groups targeting exercise behavior (N = 1050) were pooled, and analyses assessed differences in TTM constructs between the three groups at baseline, 12 months, and 24 months. Findings indicated that relapsers tended to use TTM variables similarly to

APA, Harvard, Vancouver, ISO, and other styles

30

Pageaux, G.-P., J. Michel, V. Coste, et al. "Alcoholic cirrhosis is a good indication for liver transplantation, even for cases of recidivism." Gut 45, no. 3 (1999): 421–26. http://dx.doi.org/10.1136/gut.45.3.421.

Full text

Abstract:

BACKGROUND/AIMSAlcoholic cirrhosis remains a controversial indication for liver transplantation, mainly because of ethical considerations related to the shortage of donor livers. The aim of this study was to review experience to date, focusing on survival rates and complications, and the effect of alcohol relapse on outcome and alterations in marital and socioprofessional status.METHODSThe results for 53 patients transplanted for alcoholic cirrhosis between 1989 and 1994 were compared with those for 48 patients transplanted for non-alcoholic liver disease. The following variables were analysed

APA, Harvard, Vancouver, ISO, and other styles

31

Purdum, Anna, Ryan Tieu, Sheila R. Reddy, and Michael Broder. "Total 1-year cost of diffuse large B-cell lymphoma (DLBCL) beyond first line (1L) therapy: A retrospective cohort analysis." Journal of Clinical Oncology 35, no. 15_suppl (2017): e18333-e18333. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.e18333.

Full text

Abstract:

e18333 Background: This cohort study estimated cost and healthcare use among DLBCL patients who progressed beyond 1L therapy. Methods: Using the MarketScan database, patients ≥18 years old who had R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) as 1L therapy and a claim for DLBCL (ICD-9-CM 200.7X) in the year before or 90 days after 1L start were selected for 2 cohorts: nonrelapsers who had no second line (2L) treatment for ≥2 years and 2L patients with non-R-CHOP chemotherapy after 1L. Patients not continuously enrolled for 6 months before and ≥2 years after 1L init

APA, Harvard, Vancouver, ISO, and other styles

32

Hui, C. L. M., Y. K. Li, A. W. Y. Li, et al. "Visual working memory deterioration preceding relapse in psychosis." Psychological Medicine 46, no. 11 (2016): 2435–44. http://dx.doi.org/10.1017/s0033291716000751.

Full text

Abstract:

BackgroundRelapse is distressingly common after the first episode of psychosis, yet it is poorly understood and difficult to predict. Investigating changes in cognitive function preceding relapse may provide new insights into the underlying mechanism of relapse in psychosis. We hypothesized that relapse in fully remitted first-episode psychosis patients was preceded by working memory deterioration.MethodVisual memory and verbal working memory were monitored prospectively in a 1-year randomized controlled trial of remitted first-episode psychosis patients assigned to medication continuation (qu

APA, Harvard, Vancouver, ISO, and other styles

33

Koithan, Emily M., Kai Xuan Nyoi, Timothy Hendrickson, et al. "99164 Resting Functional Connectivity of Networks Associated with Preoccupation in Alcohol Use Disorder Predicts Time to Relapse." Journal of Clinical and Translational Science 5, s1 (2021): 40. http://dx.doi.org/10.1017/cts.2021.508.

Full text

Abstract:

ABSTRACT IMPACT: Our research has the potential to impact human health by identifying a neural network that can be used to predict time to relapse in individuals with alcohol use disorder. OBJECTIVES/GOALS: Preoccupation towards alcohol use (e.g. craving, rumination, and poor executive control) is a maladaptive behavior associated with relapse risk. We investigated whether alterations in resting state networks known to mediate preoccupation could predict time to relapse in alcohol use disorder (AUD). METHODS/STUDY POPULATION: 50 participants with alcohol use disorder (AUD) (Age: M=41.76, SD=10

APA, Harvard, Vancouver, ISO, and other styles

34

Naciri Bennani, Hamza, Lionel Elimby, Florian Terrec, et al. "Kidney Transplantation for Focal Segmental Glomerulosclerosis: Can We Prevent Its Recurrence? Personal Experience and Literature Review." Journal of Clinical Medicine 11, no. 1 (2021): 93. http://dx.doi.org/10.3390/jcm11010093.

Full text

Abstract:

Background: Primary focal segmental glomerulosclerosis (FSGS) is associated with a high risk of recurrence after kidney transplantation with a major risk of graft loss despite preventive or curative treatments. Aim: to assess graft survival in FSGS kidney-transplant recipients and to compare those that had a relapse with those that had no relapse. Patients/Methods: we included 17 FSGS kidney-transplant recipients between January 2000 and January 2020, separated retrospectively into two groups (recurrences: n = 8 patients; no recurrences: n = 9 patients). FSGS recurrence was defined as having p

APA, Harvard, Vancouver, ISO, and other styles

35

Pierre, N., V. A. Huynh-Thu, M. Allez, et al. "OP12 Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn’s Disease patients stopping infliximab." Journal of Crohn's and Colitis 15, Supplement_1 (2021): S011—S013. http://dx.doi.org/10.1093/ecco-jcc/jjab075.011.

Full text

Abstract:

Abstract Background In Crohn’s disease (CD), biologics can induce mucosal healing and stable remission. After reaching this target, treatment de-escalation could be considered but the risk of relapse needs to be estimated. Current biomarkers used to predict relapse (C-reactive protein: CRP, faecal calprotectin) offer a limited prognostic capacity. Furthermore, they only monitor inflammation while we recently highlighted various and distinct pathological processes associated with the risk of short-term (&lt;6 months) and mid/long-term (&gt;6 months) relapse in CD patients stopping infli

APA, Harvard, Vancouver, ISO, and other styles

36

Tarshish, P., J. N. Tobin, J. Bernstein, and C. M. Edelmann. "Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children." Journal of the American Society of Nephrology 8, no. 5 (1997): 769–76. http://dx.doi.org/10.1681/asn.v85769.

Full text

Abstract:

The ability to predict the course in children with newly diagnosed minimal change nephrotic syndrome (MCNS) may have significant therapeutic implications. Previous attempts based on data available at disease onset have not been successful. Therefore, it was investigated whether characterization of the initial response to adrenocortical steroids and the course during the early months of disease are predictive of the subsequent outcome. Three hundred-eighty-nine children with MCNS, diagnosed at onset, were treated with standard prednisone regimens and monitored for up to 17 yr (mean, 9.4 yr). Th

APA, Harvard, Vancouver, ISO, and other styles

37

Bottiroli, Sara, Marta Allena, Grazia Sances, et al. "Changes in anxiety and depression symptoms associated to the outcome of MOH: A post-hoc analysis of the Comoestas Project." Cephalalgia 38, no. 4 (2017): 646–54. http://dx.doi.org/10.1177/0333102417704415.

Full text

Abstract:

Aims To evaluate the impact of treatment success on depression and anxiety symptoms in medication-overuse headache (MOH) and whether depression and anxiety can be predictors of treatment outcome. Methods All consecutive patients entering the detoxification program were analysed in a prospective, non-randomised fashion over a six-month period. Depression and anxiety were assessed using the Hospital Anxiety and Depression Scale. Results A total of 663 MOH patients were evaluated, and 492 completed the entire protocol. Of these, 287 ceased overuse and reverted to an episodic pattern (responders)

APA, Harvard, Vancouver, ISO, and other styles

38

D’Anna, G., F. Rotella, A. Ballerini, and V. Ricca. "Therapeutic drug monitoring of LAI antipsychotics as a predictor of clinical relapse: a one-year follow-up." European Psychiatry 65, S1 (2022): S198. http://dx.doi.org/10.1192/j.eurpsy.2022.520.

Full text

Abstract:

Introduction Clinical relapses in schizophrenia remain a frequent event. Long-acting injectable (LAI) antipsychotics enhance adherence, but low blood levels can sometimes be observed despite an adequate posology. Nonetheless, the evaluation of this parameter is uncommon in clinical practice. Objectives To explore the potential advantages of therapeutic drug monitoring (TDM) of LAIs as a predictor of relapse in clinically stable outpatients with schizophrenia. Methods 44 individuals who had reached the pharmacokinetic steady state of LAI treatment (paliperidone, olanzapine, aripiprazole) underw

APA, Harvard, Vancouver, ISO, and other styles

39

Levhar, N., R. Hadar, T. Braun, et al. "DOP09 Models for predicting Crohn Disease (CD) exacerbation using serum and fecal metabolomics." Journal of Crohn's and Colitis 18, Supplement_1 (2024): i88—i89. http://dx.doi.org/10.1093/ecco-jcc/jjad212.0049.

Full text

Abstract:

Abstract Background Metabolites, produced endogenously or derived from the gut microbiome, are key mediators and effectors of many cellular functions, but there are only scant data on their temporal changes along CD course. We analyzed the dynamics of serum and fecal metabolome in a prospective cohort of quiescent CD patients over 2 years or until the occurrence of a clinical flare, aiming to identify whether changes in the metabolome precede and predict a clinical relapse. Methods Untargeted metabolomics was performed using LC/MS. Multivariate analyses in MaAsLin2 were applied to identify dif

APA, Harvard, Vancouver, ISO, and other styles

40

Ogawa, Chitose, Akira Ohara, Atsushi Manabe, et al. "Prognostic Factors for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL): A Report from Tokyo Children’s Cancer Study Group (TCCSG) Study L95-14 and L-99-15." Blood 108, no. 11 (2006): 1884. http://dx.doi.org/10.1182/blood.v108.11.1884.1884.

Full text

Abstract:

Abstract More than 70% of children with ALL enjoy a long-term event-free survival (EFS), however, the rest of them still suffer from a relapse and the treatment for relapsed ALL is not always successful. The treatment results of childhood ALL with a first relapse were retrospectively analyzed to determine prognostic factors. Of the 1336 children enrolled on the TCCSG L95-14 and L99-15 studies, diagnosed between 1995 and 2003, 224 suffered from a relapse before March 2005. The relapsed patients were treated differently according to the protocol of each institution. The potential prognostic fact

APA, Harvard, Vancouver, ISO, and other styles

41

Chowdhury, T. A., and P. H. Dyer. "Clinical, biochemical and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis treated with anti-thyroid drugs." Journal of Internal Medicine 244, no. 4 (1998): 293–97. http://dx.doi.org/10.1046/j.1365-2796.1998.00320.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Parker, Gordon, Penny Johnston, and Linda Hayward. "Prediction of Schizophrenic Relapse Using the Parental Bonding Instrument." Australian & New Zealand Journal of Psychiatry 22, no. 3 (1988): 283–92. http://dx.doi.org/10.3109/00048678809161209.

Full text

Abstract:

After admission, 57 schizophrenic patients completed two versions of the Parental Bonding Instrument (PBI) to assess perceived recent and earlier parenting attributes. The parents were also assessed using the Camberwell Family Interview to generate Expressed Emotion (EE) scores. The schizophrenic patients, compared to matched non-clinical controls, reported a significantly greater chance (50% vs 26%) of exposure to “affectionless control” from their father. Nine months later, the subjects were re-Interviewed and their relapse status determined. The PBI measure assessing parenting over the firs

APA, Harvard, Vancouver, ISO, and other styles

43

Poordad, F. Fred, and Steven L. Flamm. "Virological relapse in chronic hepatitis C." Antiviral Therapy 14, no. 3 (2008): 303–13. http://dx.doi.org/10.1177/135965350901400314.

Full text

Abstract:

Approximately one-third of all patients infected with hepatitis C virus (HCV) genotype 1 who complete pegylated interferon α-based therapy and have undetectable serum HCV RNA at the end of treatment will experience relapse. Although relapse is a common outcome of therapy, its pathology and strategies for optimal management are poorly understood; however, optimized ribavirin dosing is recognized as pivotal in mitigating relapse. Recent data also suggest that early viral kinetics might help identify particular patient groups, such as slow responders, who are predisposed to relapse. This review p

APA, Harvard, Vancouver, ISO, and other styles

44

Newton Bishop, J. A., S. Beswick, J. Randerson-Moor, et al. "Serum vitamin D levels, VDR, and survival from melanoma." Journal of Clinical Oncology 27, no. 15_suppl (2009): 9016. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.9016.

Full text

Abstract:

9016 Background: Vitamin D has pleiotropic effects, which may moderate the interaction between patients and their tumors. Two studies were carried out to test the hypothesis that higher vitamin D levels reduce the risk of relapse from melanoma. Methods: A pilot retrospective case-control study in 271 melanoma patients suggested that vitamin D may protect against recurrence of melanoma. We then tested these findings in a survival analysis in a cohort of 872 cases recruited to the Leeds Melanoma Cohort (median follow up of 4.7 years). Results: Pilot study Results suggested that taking vitamin D

APA, Harvard, Vancouver, ISO, and other styles

45

Beck, A., T. Wüstenberg, J. Wrase-Post, et al. "FC18-04 - Cue-induced brain activation mediates subsequent relapse in abstinent alcohol-dependent patients." European Psychiatry 26, S2 (2011): 1913. http://dx.doi.org/10.1016/s0924-9338(11)73617-3.

Full text

Abstract:

IntroductionIn alcoholism, one relevant mechanism contributing to relapse is the exposure to stimuli that are associated with alcohol intake. Such conditioned cues can elicit conditioned responses like alcohol craving and consumption. In the last decade, considerable progress has been made in identifying basic neuronal mechanisms that underlie cue-induced alcohol craving.Objectives/ aimsWe explored whether functional brain activation during exposure to alcohol-associated stimuli is related to the prospective relapse risk in detoxified alcohol-dependent patients.Methods46 alcohol-dependent and

APA, Harvard, Vancouver, ISO, and other styles

46

d’Angelo, Debora Mariarita, Marina Attanasi, Giulia Di Donato, et al. "The Role of Serum Calprotectin in Defining Disease Outcomes in Non-Systemic Juvenile Idiopathic Arthritis: A Pilot Study." International Journal of Molecular Sciences 24, no. 2 (2023): 1671. http://dx.doi.org/10.3390/ijms24021671.

Full text

Abstract:

Serum calprotectin (MRP8/14) is currently being studied as a promising biomarker of disease activity and outcome in patients with juvenile idiopathic arthritis (JIA) but the data in the literature are conflicting. The aim of our study was to investigate the potential role of serum calprotectin as biomarker of disease activity and flare/remission in a group of nsJIA patients during a follow-up period of 18 months. In this prospective longitudinal study, two groups of patients with ns-JIA (55 active patients and 56 patients in remission according to Wallace’s criteria) and a control group (50 ch

APA, Harvard, Vancouver, ISO, and other styles

47

Honap, S., S. Kim, E. Whettlock, et al. "P0169 Relapse of ulcerative colitis on dose reduction of tofacitinib is associated with markers of T-cell activation but not clinical features: a prospective, multicentre observational study." Journal of Crohn's and Colitis 19, Supplement_1 (2025): i566—i567. https://doi.org/10.1093/ecco-jcc/jjae190.0343.

Full text

Abstract:

Abstract Background Tofacitinib (TOF) is an effective treatment for ulcerative colitis (UC). A relationship between dose and both response and side-effect profile is recognised for JAK inhibitors. Dose reduction from 10mg bd to 5mg bd is therefore associated with improved safety but also with a risk of relapse. The BRITE study aimed to identify clinical predictors and biomarkers of relapse in a cohort of patients with stable UC undergoing TOF dose reduction. Methods Steroid-free patients with stable UC responding to TOF 10mg bd for at least 8 weeks were followed from dose reduction to time of

APA, Harvard, Vancouver, ISO, and other styles

48

Míguez, M., Ana López-Durán, Carmela Martínez-Vispo, et al. "Health-related quality of life among smoking relapsers." Psicothema 1, no. 30 (2018): 27–32. http://dx.doi.org/10.7334/psicothema2017.61.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Mancuso, Maria E., Elena Santagostino, Maria G. Rumi, et al. "High Efficacy of Combination Therapy with Pegylated Interferon and Ribavirin in Hemophiliacs with Chronic Hepatitis C." Blood 106, no. 11 (2005): 3219. http://dx.doi.org/10.1182/blood.v106.11.3219.3219.

Full text

Abstract:

Abstract Pegylated interferon (Peg-IFN) plus ribavirin is the standard treatment for patients with chronic hepatitis C. In a multicenter open trial, we assessed the efficacy and tolerability of this treatment in 78 HIV negative hemophiliacs (age: 20–64 years) with persistently high transaminase values. Sixty-four were naïve and 14 were relapsers to IFN monotherapy. Cirrhosis was clinically detected in 12 patients (15%). HCV genotype was 1 in 69%, 2a/c in 14%, 3a in 14% and 4 in 3%. Peg-IFN alpha-2b was given subcutaneously at doses of 1.5 mcg/Kg/week for 48 weeks in genotypes 1 and 4 and for

APA, Harvard, Vancouver, ISO, and other styles

50

Rossi, P., JV Faroni, and G. Nappi. "Medication Overuse Headache: Predictors and Rates of Relapse in Migraine Patients With Low Medical Needs. A 1-Year Prospective Study." Cephalalgia 28, no. 11 (2008): 1196–200. http://dx.doi.org/10.1111/j.1468-2982.2008.01659.x.

Full text

Abstract:

The aim of this study was to evaluate the rates and predictors of relapse, after successful drug withdrawal, in migraine patients with medication overuse headache (MOH) and low medical needs. The study population, study design, inclusion criteria and short-term effectiveness of the medication withdrawal strategies have been described elsewhere (Rossi et al., Cephalalgia 2006; 26:1097). Relapsers were defined as those patients fulfilling, at follow-up, the new International Classification of Headache Disorders, 2nd edn, appendix criteria for MOH. Complete datasets were available for 83 patients

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!